News

NBC Los Angeles5d
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Fake Ozempic drugs found in US drug supply, FDA warns
The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...
Less expensive Ozempic, Wegovy copies restricted after federal court ruling
A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Will Indians get blockbuster weight-loss drugs at cost of cheaper insulin?
Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...
24/7 Wall St.8d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
NJBIZ1d
Novo Nordisk scores court win against GLP-1 copycat compounders
A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.